Source: Eur Respir J 2014; 43: 1240-1242
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Riely Gregory J., Travis William D.. Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?. Eur Respir J 2014; 43: 1240-1242

Member's Comments

No comment yet.

Related content which might interest you: TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy Source: Eur Respir J 2012; 39: 1437-1442 Year: 2012 Contribution of tumor markers to pretreatment staging of operable lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 360s Year: 2003 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease Source: Eur Respir J 2014; 43: 1439-1447 Year: 2014 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 Chemotherapy in advanced non small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Age and stage at presentation in lung cancer Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Should the treatment of advanced lepidic adenocarcinoma be adapted to the pathological subtype? Source: Eur Respir J 2015; 46: 1259-1261 Year: 2015 Stage I-IIIa small cell lung cancer (SCLC): multimodal therapy including surgery Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer? Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Objective measurement of tumor central location can predict nodal involvement in patients with cT1N0M0 non-small cell lung cancer Source: Virtual Congress 2020 – Screening and early lung cancer Year: 2020 Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Source: Eur Respir J 2010; 35: 202-215 Year: 2010 Pulmonary re-biopsy in non–small-cell lung cancer (NSCLC) locally advanced or metastatic  with EGFR-T790M resistance. Source: International Congress 2018 – Bronchoscopy and transthoracic ultrasound Year: 2018